Año 2021 / Volumen 113 / Número 11
Original
Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival

770-775

DOI: 10.17235/reed.2021.7638/2020

Carles Iniesta Navalón, Maite Gil Candel, Ignacio Salar Valverde, Isabel Nicolás de Prado, Rosa Gómez Espín, Lorena Rentero Redondo,

Resumen
Background: efficacy and safety were evaluated after switching to a biosimilar infliximab (CPT-13) in patients with inflammatory bowel disease (IBD). However, few cohort studies compare the pharmacokinetic profiles, immunogenicity, and safety of the reference infliximab (IFX) and CPT-13 in a real clinical setting. Objective: to compare the pharmacokinetic profiles and drug survival on the long term of reference IFX and CPT-13 at weeks 54 and 104. A secondary objective was to determine the long-term immunogenicity and safety profile of CPT-13 in patients with IBD in a real clinical setting. Methods: a retrospective, observational cohort analysis was performed in a single center, including patients with IBD under treatment with reference IFX or CPT-13. Serum drug concentrations were compared to determine if there were any significant differences in pharmacokinetic outcomes between reference IFX and CPT-13 at 26, 54, 78, and 104 weeks. The drug survival of reference IFX and CPT-13 was determined at weeks 54 and 104. Results: one hundred and six patients were included during the study period. Forty-five (42.5 %) patients received CPT-13 and 61 (57.5 %) received reference IFX. A total of 347 serum samples were analyzed and no significant differences were observed between reference IFX and CPT-13. The percentage of patients who achieved serum concentrations within the target therapeutic range was similar in both groups (74.1 % for reference IFX and 72.5 % for CPT-13, p = 0.741). At week 54, withdrawal rates for reference IFX and CPT-13 were 11.5 % and 20.0 %, respectively (p = 0.226), whereas at week 104 they were 26.2 % and 28.9 %, respectively (p = 0.761). Conclusion: the pharmacokinetic characteristics and incidence of immunogenicity of CPT-13 in a real clinical setting are comparable to those of the infliximab originator. The two products also have similar long-term drug survival and the same safety profile.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: The ACCENT I randomised trial. Lancet 2002;359:1451-9. DOI: 10.1016/S0140-6736(02)08512-4
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2005;353:2462-76. DOI: 10.1056/NEJMoa050516
3. Kurti Z, Gonczi L, Lakatos PL. Progress with infliximab biosimilars for inflammatory bowel disease. Expert Opin Biol Ther 2018;18:633-40. DOI: 10.1080/14712598.2018.1469620
4. Gonczi L, Gecse KB, Vegh Z, et al. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab after One Year in a Prospective Nationwide Cohort. Inflamm Bowel Dis 2017;23:1908-15. DOI: 10.1097/MIB.0000000000001237
5. Papamichael K, Stappen T Van, Jairath V, et al. Review article: Pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther 2015;42:1158-69. DOI: 10.1111/apt.13402
6. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study. Ann Rheum Dis 2013;72:1613-20. DOI: 10.1136/annrheumdis-2012-203090
7. Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2017;76:346-54. DOI: 10.1136/annrheumdis-2015-208783
8. Arguëlles-Arias F, Guerra Veloz MF, Perea Amarillo R, et al. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. Eur J Gastroenterol Hepatol 2017;29:1290-5. DOI: 10.1097/MEG.0000000000000953
9. Komaki Y, Yamada A, Komaki F, et al. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;45:1043-57. DOI: 10.1111/apt.13990
10. Danese S, Fiorino G, Raine T, et al. ECCO Position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohn’s Colitis 2017;1:26-34. DOI: 10.1093/ecco-jcc/jjw198
11. Bronswijk M, Moens A, Lenfant M, et al. Evaluating Efficacy, Safety, and Pharmacokinetics after Switching from Infliximab Originator to Biosimilar CT-P13: Experience from a Large Tertiary Referral Center. Inflamm Bowel Dis 2020;26(4):628-34. DOI: 10.1093/ibd/izz167
12. Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017;389:2304-16. DOI: 10.1016/S0140-6736(17)30068-5
13. Smits LJT, Grelack A, Derikx LAAP, et al. Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease. Dig Dis Sci 2017;62:3117-22. DOI: 10.1007/s10620-017-4661-4
14. Smits LJT, Esch AAJ Van, Derikx LAAP, et al. Drug survival and immunogenicity after switching from remicade to biosimilar CT-P13 in inflammatory bowel disease patients: Two-year follow-up of a prospective observational cohort study. Inflamm. Bowel Dis 2019;25:172-9. DOI: 10.1093/ibd/izy227
15. Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet 2019;393:1699-707. DOI: 10.1016/S0140-6736(18)32196-2
16. Berends SE, Strik AS, Selm JC Van, et al. Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients with Crohn’s Disease. Ther. Drug Monit 2018;40:202-11. DOI: 10.1097/FTD.0000000000000494
17. Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn’s Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials. Clin Ther 2011;33:946-64. DOI: 10.1016/j.clinthera.2011.06.002
18. Mitrev N, Casteele N Vande, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;46:1037-53. DOI: 10.1111/apt.14368
19. Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatology Venereol 2016;30:1148-58. DOI: 10.1111/jdv.13611
20. Smits LJT, Derikx LAAP, Jong DJ de, et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: A prospective observational cohort study. J Crohn’s Colitis 2016;10:1287-93. DOI: 10.1093/ecco-jcc/jjw087
21. Cohen SB, Alten R, Kameda H, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther 2018;20:1-13. DOI: 10.1186/s13075-018-1646-4
22. Santacana E, Rodríguez-Alonso L, Padullés A, et al. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. 2020; Ther Drug Monit 2020;42:102-10. DOI: 10.1097/FTD.0000000000000669
23. Gil Candel M, Gascón Cánovas JJ, Espín RG, et al. Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients. Rev Esp Enf Dig 2020;112:590-7. DOI: 10.17235/reed.2020.6857/2020
24. Mitchell RA, Shuster C, Shahidi N, et al. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. Can J Gastroenterol Hepatol 2016;2016:5203898. DOI: 10.1155/2016/5203898
25. Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:1655-68. DOI: 10.1016/j.cgh.2019.03.037
26. Sparrow MP, Papamichael K, Ward MG, et al. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J. Crohn’s Colitis 2020;14:542-56. DOI: 10.1093/ecco-jcc/jjz162
27. Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs 2017;31:299-316. DOI: 10.1007/s40259-017-0231-8
28. Llinares-Tello F, Rosas-Gómez de Salazar J, Senabre-Gallego JM, et al. Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol Int 2014;34:1701-8. DOI: 10.1007/s00296-014-3032-0
29. Thomas SS, Borazan N, Barroso N, et al. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs 2015;29:241-58. DOI: 10.1007/s40259-015-0134-5
30. Atiqi S, Hooijberg F, Loeff FC, et al. Immunogenicity of TNF-Inhibitors. Front Immunol 2020;11:1-13. DOI: 10.3389/fimmu.2020.00312
31. Razanskaite V, Bettey M, Downey L, et al. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. J Crohns Colitis 2017;11:690-6. DOI: 10.1093/ecco-jcc/jjw216
32. Feagan BG, Lam G, Ma C, Lichtenstein GR. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther 2019;49:31-40. DOI: 10.1111/apt.14997
33. Subedi S, Gong Y, Chen Y, et al. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther 2019;2491-502. DOI: 10.2147/DDDT.S200147
34. Meyer A, Rudant J, Drouin J, et al. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: A French equivalence study. Ann Intern Med 2019;170:99-107. DOI: 10.7326/M18-1512
Artículos relacionados

Carta

Linfoma T hepatoesplénico y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2023.9472/2023

Carta

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Revisión

Enfermedad inflamatoria intestinal y trasplante de órganos sólido

DOI: 10.17235/reed.2020.7361/2020

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Caso Clínico

Lesiones serradas en pacientes con enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2019.5910/2018

Editorial

Redes sociales online y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2018.5496/2018

Carta al Editor

Hipertensión portal idiopática por tiopurinas

DOI: 10.17235/reed.2018.5256/2017

Instrucciones para citar
Iniesta Navalón C, Gil Candel M, Salar Valverde I, Nicolás de Prado I, Gómez Espín R, Rentero Redondo L, et all. Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival. 7638/2020


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 778 veces.
Este artículo ha sido descargado 181 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 08/11/2020

Aceptado: 14/01/2021

Prepublicado: 25/01/2021

Publicado: 05/11/2021

Tiempo de revisión del artículo: 61 días

Tiempo de prepublicación: 78 días

Tiempo de edición del artículo: 362 días


Compartir
Este artículo ha sido valorado por 1 lectores .
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas